DDMAC: FERTILITY DRUG RISKS MINIMIZED IN PROMOTIONS

Washington Drug Letter
KEYWORDS FDA / Warning
A A

Promotional materials for Organon's Follistim fertility drug minimized the drug's risks and made unsubstantiated superiority claims, according to an untitled letter released by the FDA late December.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00